Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-10-09FDA Approved: LAMICTAL XR — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal XR (lamotrigine) submitted by GlaxoSmithKline LLC. The action relates to Lamictal XR un…
-
CLINICAL_TRIALS trial_result · 2020-10-09Clinical Trial Update: Conscious Sedation for Epilepsy Surgery [NA]
A completed clinical trial studying conscious sedation for epilepsy surgery; results posted in 2020.
-
FDA approval · 2020-10-06FDA Approved: PHENYTOIN SODIUM — Supplemental Application (Acella Pharmaceuticals, LLC)
FDA approved a supplemental application for phenytoin sodium from Acella Pharmaceuticals, LLC.
-
FDA approval · 2020-10-02FDA Approved: LORAZEPAM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Lorazepam from Amneal Pharmaceuticals LLC. The approval updates labeling/indication for the Lora…
-
FDA approval · 2020-10-02FDA Approved: VIGABATRIN — Supplemental Application (Cipla USA, Inc.)
FDA approved a supplemental application for Vigabatrin by Cipla USA, Inc., granting an additional approval under the ANDA for Vigabatrin, ty…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2020-10-02FDA Approved: VIGABATRIN — Supplemental Application (Par Health USA, LLC)
The FDA approved a supplemental application for Vigabatrin from Par Health USA, LLC, resulting in updated labeling for the product.
-
CLINICAL_TRIALS trial_result · 2020-10-01Clinical Trial Update: Pilot Study of Melatonin and Epilepsy [Phase 2]
Phase 2 pilot study investigating the use of melatonin in epilepsy was completed, with results posted in 2020.
-
FDA approval · 2020-09-30FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for Keppra (levetiracetam) from UCB, Inc.
-
FDA approval · 2020-09-30FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA XR (levetiracetam), the extended-release formulation, submitted by UCB, Inc.
-
FDA label_change · 2020-09-30FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for Keppra (levetiracetam) filed by UCB, Inc., resulting in labeling changes for the product.
-
FDA approval · 2020-09-29FDA Approved: GABAPENTIN — Supplemental Application (ScieGen Pharmaceuticals, Inc.)
FDA approved a supplemental application for Gabapentin from ScieGen Pharmaceuticals, Inc.
-
FDA approval · 2020-09-28FDA Approved: PHENYTOIN SODIUM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for phenytoin sodium by Hikma Pharmaceuticals USA Inc., under the ANDA pathway.
-
CLINICAL_TRIALS trial_result · 2020-09-22Clinical Trial Update: IV Lacosamide: The Safety of Intravenous Lacosamide [Phase 3]
Phase 3 study assessing the safety of intravenous lacosamide in epilepsy has completed.
-
CLINICAL_TRIALS trial_result · 2020-09-22Clinical Trial Update: The Safety of Intravenous Lacosamide [Phase 4]
Phase 4 trial update assessing the safety of intravenous lacosamide in epilepsy.
-
FDA approval · 2020-09-18FDA Approved: LEVETIRACETAM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for levetiracetam from Torrent Pharmaceuticals Limited, granting the requested modification under th…
-
CLINICAL_TRIALS trial_result · 2020-09-18Clinical Trial Update: Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With Epilepsy [Phase 2]
Phase 2 clinical trial update for diazepam buccal film in adults with epilepsy (interictal and ictal-periictal states) completed; results po…
-
FDA approval · 2020-09-16FDA Approved: GABAPENTIN — Supplemental Application (ACI Healthcare USA, Inc.)
FDA approved a supplemental application for gabapentin from ACI Healthcare USA, Inc., updating the regulatory status of the product.
-
FDA approval · 2020-09-10FDA Approved: LEVETIRACETAM — Supplemental Application (Apotex Corp.)
The FDA approved Apotex Corp.'s supplemental application for a generic version of levetiracetam, enabling its sale as a generic antiepilepti…
-
CLINICAL_TRIALS trial_result · 2020-09-09Clinical Trial Update: Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children [Phase 4]
Phase 4 trial evaluating dietary and immunological management strategies for refractory epilepsy in children.
-
FDA approval · 2020-09-08FDA Approved: GABAPENTIN — Supplemental Application (Exelan Pharmaceuticals, Inc.)
FDA approved a supplemental application for gabapentin from Exelan Pharmaceuticals, Inc. under an ANDA.
-
FDA approval · 2020-08-31FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal (lamotrigine) submitted by GlaxoSmithKline LLC.
-
FDA label_change · 2020-08-31FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)
FDA supplemental application approval for LAMICTAL ODT (lamotrigine) by GlaxoSmithKline, seeking changes to the product labeling.
-
FDA label_change · 2020-08-31FDA Approved: LAMICTAL XR — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Lamictal XR (lamotrigine) submitted by GlaxoSmithKline LLC, resulting in changes to the product …
-
FDA approval · 2020-08-31FDA Approved: XCOPRI — Supplemental Application (SK Life Science, Inc.)
The FDA approved a supplemental application for XCOPRI (cenobamate) submitted by SK Life Science, Inc., resulting in updated labeling.
-
FDA label_change · 2020-08-31FDA Approved: LAMICTAL — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for Lamictal (lamotrigine) from GlaxoSmithKline, updating the product labeling.